The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oman Medical Speciality Board
Because there are no previous studies with the same methodology found, pilot study will be conducted to estimate the sample size.
Patients who are eligible to be enrolled in the study will be randomized into two group (after receiving the standard of care, 3 back to back nebulization (salbutamol and ipratropium bromide)) , the experimental group will be given epinephrine (1ml of 1:1000) as nebulization and the control group will receive salbutamol nebulization as 4th nebulization.
PRAM score with calculated before and at 60, 80, 100 min after the treatment.
Age
3–13
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
* Pediatric age group 3 - 12 years
* known to have asthma
* Initial PRAM Score showed moderate to severe asthma exacerbation
You may not be if
* History of lung or upper airway disease other than asthma:
* bronchiolitis, anaphylaxis, pertussis, vocal cord dysfunction, foreign body aspiration, bronchopulmonary dysplasia, cystic fibrosis and lower airway mass effects
* History of congenital heart disease or cardiac arrhythmia or heart failure.
* Known hypertension
* Impending respiratory failure (Decreasing mental status, Respiratory fatigue, Impending respiratory arrest, Hypoxemia (pO2 \< 60 mmHg), pCO2 could be normal or high)
* Allergy or hypersensitivity to epinephrine
* Patient/Parents refusal to participate in the study